Mallinckrodt Pharmaceuticals
383 articles about Mallinckrodt Pharmaceuticals
-
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
8/15/2019
Mallinckrodt plc announced positive top-line results from its pivotal Phase 3 CONFIRM clinical study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1.
-
After Suspending Generics Spin-Off, Mallinckrodt Eyes Potential FDA Approval of Liver Disease Drug
8/15/2019
Mallinckrodt’s experimental drug terlipressin hit the mark in a late-stage liver disease trial. Mallinckrodt said terlipressin met its primary endpoint in reversing three components of hepatorenal syndrome type 1. -
Mallinckrodt Announces Publication of Results of Phase 1b Clinical Trial of StrataGraft® Regenerative Tissue in Burns
8/13/2019
Mallinckrodt plc announced publication of results of its Phase 1b clinical trial of StrataGraft®, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries.
-
First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)
8/12/2019
Trial is to Assess Pharmacokinetics, Pharmacodynamics and Safety of the Oral Administration of MNK-6106 in Patients with HE
-
Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-off
8/6/2019
Mallinckrodt plc, a global biopharmaceutical company, reported results for the three months ended June 28, 2019.
-
Mallinckrodt Delays Planned Generics Spin-Off Due to Opioid Litigation and Market Conditions
8/6/2019
Mallinckrodt said it remains committed to becoming an “innovation-driven specialty brands business.” -
Mallinckrodt to Present at Wells Fargo Securities 2019 Healthcare Conference
8/2/2019
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Thursday, Sept. 5, 2019, at the Wells Fargo Securities 2019 Healthcare Conference at the Westin Copley Place, 10 Huntington Ave., Boston.
-
Clinical Catch-up for July 15-19
7/22/2019
Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more. -
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
7/18/2019
Mallinckrodt Chief Scientific Officer Steven Romano, M.D. joins Silence Board as non-executive Director
-
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
7/18/2019
Collaboration advances Silence's proprietary platform in the growing field of RNAi technology
-
The companies will develop therapies that target the complement cascade, a group of proteins known to play a role in autoimmune diseases.
-
Release of Federal Database Reveals 76 Billion Opioid Pills Were Sold in the U.S. From 2006-2012
7/17/2019
A federal judge ordered that information on sales of opioids up to the year 2013 could be released. -
A disproportionate number of ALS patients on the investigational drug developed pneumonia.
-
Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)
7/16/2019
Mallinckrodt plc announced that it is permanently discontinuing its Phase 2B study designed to assess the efficacy and safety of Acthar® Gel as an investigational treatment for amyotrophic lateral sclerosis.
-
Mallinckrodt to Report Earnings Results for Second Quarter 2019
7/1/2019
Mallinckrodt plc, a global biopharmaceutical company, announced that it will report second quarter 2019 earnings results for the period ending June 28, 2019 on Tuesday, Aug. 6, 2019.
-
Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)
6/24/2019
Mallinckrodt plc, confirmed it has achieved 50 percent patient enrollment in the company's Phase 2B study designed to assess the efficacy and safety of Acthar® Gel as an investigational treatment for amyotrophic lateral sclerosis.
-
All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)
6/13/2019
Study met primary outcome measure; 63 percent of patients with persistently active RA achieved low disease activity (LDA) as assessed by DAS28-ESR¹ at Week 12
-
Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
6/11/2019
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Tuesday, June 25, 2019, at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference at the Mandarin Oriental, 80 Columbus Circle, New York.
-
Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference
5/31/2019
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, will present on Wednesday, June 19, 2019, at the Raymond James Life Sciences and MedTech Conference at the Lotte New York Palace, 455 Madison Ave, New York.
-
Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)
5/29/2019
Mallinckrodt plc, a global specialty biopharmaceutical company, is reporting data1 from the open-label part of the Phase 4, multicenter study assessing the efficacy and safety of Acthar® Gel in patients with persistently active rheumatoid arthritis who were previously treated with disease-modifying anti-rheumatic drugs and corticosteroids.